^{The Zhitong Finance App has learned that AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) announced that Dazuoyou® (English product name: Datroway ®, generic name: dedabotumab for injection) has been approved by the China National Drug Administration (NMPA) to treat adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for treatment with PD-1/PD-L1 inhibitors.} Dedabotumab is a targeted TROP2 antibody-conjugated drug (ADC) developed using a unique technology. It was developed by Daiichi Sankyo and developed and commercialized in collaboration with AstraZeneca and Daiichi Sankyo.

According to the data, this approval is based on the positive results of the Tropion-Breast02 global phase III study. Dedabotumab has been approved in more than 35 countries and regions around the world to treat adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for treatment with PD-1/PD-L1 inhibitors. This approval is the second indication that delabotumab has been approved in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.